Carboline derivatives useful in the inhibition of angiogenesis

Details Carboline derivatives useful in the inhibition of angiogenesis Carboline derivatives useful in the inhibition of angiogenesis

2005-03-15

2009-10-13

Desai, Rita J (Department: 1625)

Organic compounds -- part of the class 532-570 series

Organic compounds

Heterocyclic carbon compounds containing a hetero ring...

C514S292000

Reexamination Certificate

active

07601840

ABSTRACT:
In accordance with the present invention, compounds that inhibit the expression of VEGF post-transcriptionally have been identified, and methods for their use provided. In one aspect of the invention, compounds useful in the inhibition of VEGF production, in the inhibition of angiogenesis, and/or in the treatment of cancer, diabetic retinopathy or exudative macular degeneration are provided. In another aspect of the invention, methods are provided for the inhibition of VEGF production, the inhibition of angiogenesis, and/or the treatment of cancer, diabetic retinopathy or exudative macular degeneration using the compounds of the invention.

REFERENCES:
patent: 3492304 (1970-01-01), Shavel et al.
patent: 4014890 (1977-03-01), Welch, Jr. et al.
patent: 4720484 (1988-01-01), Vincent et al.
patent: 4754038 (1988-06-01), Abou-Gharbia
patent: 5039801 (1991-08-01), Brossi et al.
patent: 5120543 (1992-06-01), Hagin et al.
patent: 5166204 (1992-11-01), Nagai et al.
patent: 5206377 (1993-04-01), McAfee
patent: 5382569 (1995-01-01), Cody et al.
patent: 5403851 (1995-04-01), D'Orlando et al.
patent: 5451600 (1995-09-01), Banner et al.
patent: 5580878 (1996-12-01), D'Orlando et al.
patent: 5622960 (1997-04-01), Pommier et al.
patent: 5633388 (1997-05-01), Diana et al.
patent: 6043252 (2000-03-01), Bombrun
patent: 6048868 (2000-04-01), Fourtillan et al.
patent: 6175015 (2001-01-01), Yuan et al.
patent: 6235718 (2001-05-01), Balasubramanium et al.
patent: 6306870 (2001-10-01), Bombrun
patent: 6331543 (2001-12-01), Garvey et al.
patent: 6350757 (2002-02-01), Goldstein et al.
patent: 6376529 (2002-04-01), Tang et al.
patent: 6514981 (2003-02-01), Tang et al.
patent: 6552017 (2003-04-01), Robichaud et al.
patent: 6630589 (2003-10-01), Giordano et al.
patent: 6635638 (2003-10-01), Sui et al.
patent: 6653132 (2003-11-01), Keshet et al.
patent: 6667152 (2003-12-01), Miles et al.
patent: 6706750 (2004-03-01), Bentley et al.
patent: 6890933 (2005-05-01), Feng et al.
patent: 2002/0016298 (2002-02-01), Hay et al.
patent: 2002/0091125 (2002-07-01), Hay et al.
patent: 2002/0128206 (2002-09-01), Hay et al.
patent: 2002/0173503 (2002-11-01), Robichaud et al.
patent: 2003/0023087 (2003-01-01), Garvey et al.
patent: 2003/0040527 (2003-02-01), Yeh et al.
patent: 2003/0130171 (2003-07-01), Schoenhard
patent: 2003/0220377 (2003-11-01), Chesworth
patent: 2004/0023947 (2004-02-01), Martin et al.
patent: 2004/0058877 (2004-03-01), Hay et al.
patent: 2004/0116458 (2004-06-01), Sawyer et al.
patent: 2004/0127482 (2004-07-01), Robichaud et al.
patent: 2004/0157834 (2004-08-01), Hay et al.
patent: 2004/0186094 (2004-09-01), Robichaud et al.
patent: 2004/0209864 (2004-10-01), Robichaud et al.
patent: 2004/0214223 (2004-10-01), Cao
patent: 2004/0214848 (2004-10-01), Schoenhard
patent: 2004/0229864 (2004-11-01), Bourrain et al.
patent: 2005/0004156 (2005-01-01), Feng et al.
patent: 2005/0054568 (2005-03-01), Ling et al.
patent: 2005/0054634 (2005-03-01), Busch et al.
patent: 2005/0267018 (2005-12-01), Blatt et al.
patent: 2005/0272759 (2005-12-01), Moon et al.
patent: 2005/0282849 (2005-12-01), Moon
patent: 2099060 (1993-12-01), None
patent: 0008249 (1981-08-01), None
patent: 0 357 122 (1990-03-01), None
patent: 0406734 (1991-01-01), None
patent: 0468789 (1992-01-01), None
patent: 0491943 (1992-07-01), None
patent: 0 549 916 (1993-07-01), None
patent: 0 549 916 (1993-08-01), None
patent: 0719837 (1995-12-01), None
patent: 0300541 (1996-03-01), None
patent: 1512397 (2005-03-01), None
patent: 1383765 (2006-12-01), None
patent: 2432025 (1980-02-01), None
patent: 2 662 940 (1991-12-01), None
patent: 3-287586 (1991-12-01), None
patent: 4-275221 (1992-09-01), None
patent: 94/10175 (1994-05-01), None
patent: 94/11378 (1994-05-01), None
patent: WO 94/10175 (1994-05-01), None
patent: 96/26207 (1996-08-01), None
patent: 96/32003 (1996-10-01), None
patent: 97/37658 (1997-10-01), None
patent: 97/43287 (1997-11-01), None
patent: 99/06390 (1999-02-01), None
patent: 00/39314 (2000-07-01), None
patent: 01/21584 (2001-03-01), None
patent: 01/21589 (2001-03-01), None
patent: 01/47887 (2001-07-01), None
patent: 01/87038 (2001-11-01), None
patent: 01/87038 (2001-11-01), None
patent: 02/051805 (2002-07-01), None
patent: 02/088123 (2002-11-01), None
patent: 03/033496 (2003-04-01), None
patent: 03/051841 (2003-06-01), None
patent: 03/087815 (2003-10-01), None
patent: 03/099821 (2003-12-01), None
patent: 03/103656 (2003-12-01), None
patent: 2004/035047 (2004-04-01), None
patent: WO 2004/069831 (2004-08-01), None
patent: WO 2004/096766 (2004-11-01), None
patent: 2004/110999 (2004-12-01), None
patent: WO 2004/113336 (2004-12-01), None
patent: 2005/000246 (2005-01-01), None
patent: 2005/005386 (2005-01-01), None
patent: WO 2005/007672 (2005-01-01), None
patent: 2005/014543 (2005-02-01), None
patent: WO 2005/009370 (2005-02-01), None
patent: 2005/037791 (2005-04-01), None
patent: WO 2005/070930 (2005-08-01), None
patent: WO 2005/089764 (2005-09-01), None
patent: 2005/097162 (2005-10-01), None
patent: 2005/113003 (2005-12-01), None
patent: WO 2006/015035 (2006-02-01), None
patent: WO 2006/058088 (2006-06-01), None
patent: 2006/113703 (2006-10-01), None
Dorwald F. A. Side Reactions in Organic Synthesis, 2005, Wiley: VCH, Weinheim pg. IX of Preface.
Caplus English bstract WO 2002064591 Aug. 2002, Jason Sawyer et al. US equivalent 7122554.
R. Cao et al., “Synthesis and in vitro Cytotoxic Evaluation of 1,3-Bisubstituted and 1,3,9-Trisubstituted β-Carboline Derivatives,”European Journal of Medicinal Chemistry, 40:249-257 (2005).
E. Fuhrmann-Benzakein et al., “Elevated Levels of Angiogenic Cytokines in the Plasma of Cancer Patients,”Int. J. Cancer, 85:40-45 (2000).
T. Ichihara et al., “Enhancer for Carcinostatic Effect,” Derwent AN—1992-376264 (Sep. 30, 1992).
B.J.R. Nicolaus, “Symbiotic Approach to Drug Design,”Decision Making in Drug Research(F. Gross, ed., Raven Press, New York, NY), pp. 173-186 (1983).
International Search Report issued in PCT/US2005/042484 on Oct. 4, 2006.
Shanmugasundaram et al., “Synthesis and biological activity of pyrazino[3,2,1-j,k]carbazoles”,Indian Journal of Chemistry, 37b:1133-1136 (1998).
Shanmugasundaram et al., “Synthesis of 3-Phenylisoxazolo[3,4-a]carbazoles”,Zeitschrift Für Naturforschung, 54b:1202-1204 (1999).
Akiri et al., “Regulation of Vascular Endothelial Growth Factor (VEGF) Expression is Mediated by Internal Initiation of Translation and Alternative Initiation of Transcription”,Oncogene, 17:227-236 (1998).
Asano et al., “Wide Spectrum of Antitumor Activity of a Neutralizing Monoclonal Antibody to Human Vascular Endothelial Growth Factor”,Jpn. J. Cancer Res., 90:93-100 (1999).
Bergsland et al., “A Randomized Phase II Trial Comparing rhuMAb VEGF (Recombinant Humanized Monoclonal Antibody to Vascular Endothelial Cell Growth Factor) Plus 5-Fluorouracil/Leucovorin (FU/LV) to FU/LV Alone in Patients with Metastatic Colorectal Cancer”, American Society of Clinical Oncology 36thAnnual Meeting, May 2000, New Orleans, LA, USA, Abstract No. 939.
Borgström et al., “Neutralizing Anti-Vascular Endothelial Growth Factor Antibody Completely Inhibits Angiogenesis and Growth of Human Prostate Carcinoma Micro Tumors In Vivo”,Prostate, 35:1-10 (1998).
Boyer, S. J., “Small Molecule Inhibitors of KDR (VEGFR-2) Kinase: An Overview of Structure Activity Relationships”,Current Topics in Medicinal Chemistry, 2:973-1000 (2002).
Brekken et al., “Selective Inhibition of Vascular Endothelial Growth Factor (VEGF) Receptor 2 (KDR/Flk-1) Activity by a Monoclonal Anti-VEGF Antibody Blocks Tumor Growth in Mice”,Cancer Res., 60:5117-5124 (2000).
Carmeliet, Peter, “Angiogenesis in Health and Disease”,Nature Medicine, 9(6):653-660 (2003).
Carmeliet et al., “Abnormal Blood Vessel Development and Lethality in Embryos Lacking a Single VEGF Allele”Nature, 380:435-439 (1996).
Carmeliet et al., “Angiogenesis in Cancer and Other Disea

Affiliated with

Also associated with

Rating

Carboline derivatives useful in the inhibition of angiogenesis does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Carboline derivatives useful in the inhibition of angiogenesis, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Carboline derivatives useful in the inhibition of angiogenesis will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4113809